HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.
August 15, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $12 price target.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating and $12 price target from HC Wainwright & Co. suggest a positive outlook for Cocrystal Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100